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September 9, 2014 increased right heart failure (RHF) and the need for temporary right heart mechanical support. 10 Preliminary studies suggest that tricuspid valve repair at the time of LVAD implantation may improve early outcomes and reduce RHF. [11] [12] [13] [14] However, John et al 8 demonstrated increased RHF for patients undergoing concurrent tricuspid valve procedures (TVP) versus LVAD alone. It is unclear whether the increased postoperative RHF relates to the severity of preimplant TR or the TVP itself. Current International Society for Heart and Lung Transplantation guidelines suggest consideration for concurrent TVP when preimplant TR severity is moderate or greater. 7 The availability of ongoing follow-up data from the ADVANCE BTT pivotal trial for the HeartWare centrifugal design cf-LVAD (HVAD), and from the subsequent continued access protocol (CAP), affords the opportunity to examine outcomes in subsets of patients with valvular pathology. The present study reviewed patients receiving the HVAD system in the context of ADVANCE BTT and CAP to evaluate the impact of concurrent valve procedures on early outcomes.
Methods

Patients and Study Design
The ADVANCE BTT and CAP trials were conducted in compliance with Food and Drug Administration regulations for Good Clinical Practice and was approved by the institutional review board at each site. All patients or their authorized representatives provided informed consent. Study data and its collection were audited by the sponsor and the Food and Drug Administration.
All patients in this analysis were implanted with the HeartWare Ventricular Assist System (HVAD; HeartWare Inc, Framingham, MA), which is a miniaturized, implantable, centrifugal design, continuous-flow blood pump that is placed within the pericardial space, with the integrated inflow cannula surgically positioned within the left ventricle. 1 The study designs and enrollment criteria for the HeartWare ADVANCE BTT pivotal trial and CAP have been described previously. 1, 2 Briefly, ADVANCE was a prospective, multicenter clinical trial to evaluate the HVAD as BTT in 140 transplant-eligible patients with advanced heart failure requiring mechanical circulatory support. Patients were monitored for >180 days after implant or until cardiac transplantation, device explant for recovery, or death and compared with a contemporaneous group of Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)-enrolled patients who received a commercially available LVAD as a BTT. The trial met the primary end point of success to 180 days on original device or transplant and showed that HVAD group success was noninferior to the INTERMACS group (90.7% versus 90.1%, respectively; noninferiority P<0.0001). Survival at 180 days in ADVANCE in the HVAD versus control group was 94% versus 90%, respectively.
The CAP for the BTT indication enrolled 242 additional patients in 4 allotments. An interim analysis was performed in July 2012, and survival outcomes in this larger population were consistent with the original clinical trial (91% at 180 days and 84% at 360 days). 2 Quality of life scores improved significantly, and adverse event rates remained low.
In the present study, the overall patient cohort consisted of the original 140 patients from ADVANCE BTT and 242 patients from the CAP. Together, these 382 patients represent the complete HVAD BTT study cohort (Figure 1 ). This data set included all patients enrolled in the ADVANCE BTT+CAP through November, 2012, and followed until database lock in June, 2013.
For the purposes of this analysis, patients were retrospectively divided into 3 subpopulations: all patients who underwent any concurrent cardiac valve procedure during HVAD implantation (the concurrent valve procedure group), all patients who underwent isolated HVAD implantation without any other concurrent cardiac surgical procedure (the HVAD-only group), and all patients who underwent any concurrent nonvalvular cardiac procedure (the concurrent nonvalve procedure group). Included in the concurrent nonvalve procedure group were 16 patent foremen ovale closures, 7 atrial septal defect repairs, and 3 pericardial reconstructions.
For certain subanalyses, patients in the concurrent valve procedure group were further subclassified by valve position (ie, aortic, mitral, or tricuspid). Because of limitations in data collection, it was not possible to classify patients by the pathogenesis of valve dysfunction or to identify which patients underwent valve repair versus replacement. Tricuspid repairs included annuloplasty ring and less frequently deVega procedures. However, details on the specific procedures performed were not routinely collected; therefore, aortic valve, mitral valve, and TVP were defined as any surgical repair, replacement, or closure of the respective valve.
Surgical Techniques
The technique for implantation of the HVAD has been described previously. 15, 16 Patients diagnosed with valvular dysfunction were selected for concurrent cardiac valve procedures according to the clinical experience and discretion of each implanting surgeon.
Postoperative Follow-Up
Postsurgical care and anticoagulation protocols were patient-and center-specific. Clinical assessments were scheduled and conducted as reported previously. 
Outcomes
The primary outcome was a comparison of the survival between the concurrent valve procedure group and the HVAD-only group. 
Statistical Analysis
Descriptive statistics were used to evaluate baseline demographics and event incidence. Continuous data when normally distributed were presented as mean±SD; otherwise, median (range) was given.
Comparisons between groups were performed using the t test for continuous variables and the Fisher exact test for categorical variables, with a prespecified α level of 0.05 for all comparisons. 
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INTERMACS-defined adverse events were described as either percent of population affected or rate of event per patient-year of support. Survival was reported descriptively through Kaplan-Meier analysis, with follow-up censored at the time of heart transplantation or device explant for recovery or exchange. Overall survival was defined as freedom from death from any cause. The log-rank test was used to compare Kaplan-Meier curves.
Because the unadjusted rate of RHF was found to be greater for the concurrent valve group compared with HVAD alone, a multivariable analysis was conducted to identify independent risk factors for the 121 RHF and early death events (that is, including death within 30 postoperative days to conservatively include those early deaths that might have been related to undefined RHF). To find the significant variables to use in the multivariable model, a univariable risk model was first performed to find those factors which might be predictive of RHF and early death. A total of 40 covariates were considered as risk factors. Each covariate was assessed independently as a predictor by univariable analysis, and covariate influence was measured with odds ratios and accompanying P values using the Cochran-MantelHaenszel test. Covariate reduction was performed based on the univariable analysis results, using a P-value limit of <0.15, as well as the impact of potential multicolinearity. Using this method, we identified 11 covariates which were significant. These remaining covariate terms for which sufficient data were available were modeled using a logistic regression analysis to predict risk factors for the binary outcome (death within 30 days of implant or RHF). Insufficient data result in a reduction in the total number of patients because the model considers the relationship between the variables, and therefore, all patients included in the model must have complete data for each model covariate. As a result, it was required that the model covariates used include data in a total of ≥85% of the original population. SAS system software version 9.2 (SAS Institute, Cary, NC) was used for the statistical analyses.
Results
Study Groups, Baseline Characteristics, and Clinical Course
Between August 2008 and November 2012, 382 patients were implanted with HVAD as BTT. The mean time on support for patients in this analysis was 389 days, with a median time on support of 271 days. Of these 382 study patients, 262 (68.6%) underwent isolated HVAD implantation, 75 (19.6%) underwent HVAD implantation with a concurrent valve procedure, and 45 patients (11.8%) underwent concurrent nonvalvular procedures at the time of implant (Figure 1 ). The 75 valve procedures included 56 TVPs, 13 aortic valve procedures (AVP), and 6 mitral valve procedures.
Baseline characteristics of the comparator groups are summarized in Table 1 . A statistically significant difference in age was observed between the concurrent valve procedure and HVAD-only groups (51 versus 54 years, respectively; P=0.029), but there were no other notable differences between the 2 groups. Of note, in the HVAD-only group, 27.5% of the patients had moderate or severe TR preoperatively but did not undergo TVP, n=71 (secondary data not shown in table). A comparison of patients with TVP versus AVP showed that patients who underwent a TVP were significantly younger than those undergoing an AVP (48 versus 58 years; P=0.0008).
Cardiopulmonary bypass time was predictably longer in the concurrent valve procedure group versus the HVAD-only group (116±30.8 versus 72±29.3 minutes, respectively; P<0.0001); however, this did not result in longer median intensive care unit stay, which was 8 days (range, 1-50) for patients with concurrent valve procedures versus 7 days (range, 0-256) for HVAD alone or did it result in longer median hospital length of stay, which was 20 (9-86) versus 20 (8-256) days, respectively. These data are presented here as text, not included in Table 1 .
Survival
Kaplan-Meier survival estimates were similar between patients who underwent HVAD implantation alone versus those with concurrent valve procedures (Figure 2) . Survival rates at 30, 60, 180, and 365 days were 97%, 97%, 89%, and 79% for the concurrent valve procedure group and 98%, 96%, 90%, and 85% for the HVAD-only group (P=0.33). Survival in those patients with other concurrent cardiac procedures was also similar, with survival at 30, 60, 180, and 365 days at 100%, 98%, 93%, and 82%.
A comparison of patients with concurrent AVP versus TVP also showed no significant differences (Figure 3) , with 30-, 60-, 180-, and 365-day survival rates of 100%, 100%, 92%, and 92% for the AVP group and 96%, 96%, 89%, and 77% for the TVP group (P=0.35).
The outcomes of different approaches to treating tricuspid valve pathology were also analyzed. Although 56 patients were treated with a TVP, 71 patients who were diagnosed 
Adverse Events
Rates of INTERMACS-defined adverse events were similar between the 2 main comparator groups (Tables 2 and 3) , with the exception of higher rates of early (≤30 days) RHF in the concurrent valve procedure group. Early RHF occurred in 40% of concurrent valve patients versus 28% of HVAD-only patients (P=0.046). Incidence of late RHF, however, trended lower for the HVAD plus valve group compared with the HVAD-only group. Adverse events were generally similar in patients who underwent a concurrent TVP compared with those with moderate to severe tricuspid valve insufficiency that was not treated surgically. Transient ischemic attack occurring >30 days postoperatively was more frequent in patients with significant TR who did not receive TVP (0.07 events per patientyear with 5 events versus 0.00 events per patient-year with 0 events for TVP patients; P=0.014).
Patients receiving a TVP experienced significantly less late RHF than those with moderate or severe TR who were not Figure 4A and 4B depicts the percentage of patients with early and late RHF in the HVAD alone, HVAD plus concurrent valve procedures, HVAD plus TVP, and HVAD plus moderate/severe TR without concurrent procedure.
A multivariable analysis was performed to determine the significant risk factors for RHF. We used a composite (121 events) of RHF and early death (death within 30 days of implant) since early deaths might have been because of RHF that had not been fully evaluated and identified at such an early postoperative stage. There would have been sufficient time to identify RHF beyond 30 days, so we included only those deaths in the first 30 days to avoid missing any RHF events. The multivariable analysis identified TR severity and sex as significant risk factors with odds ratios of 2.9 (95% confidence interval, 1.8-4.8; P<0.0001) and 2.0 (95% confidence interval, 1.2-3.3; P=0.0053), respectively, but undergoing concurrent valve procedure was not predictive ( Figure 5 ; Table 4 ). Several variables were statistically significant predictors of RHF as identified in the univariable analysis, but these predictors did not make the multivariable model because of insufficient data. These included baseline pulmonary artery diastolic pressure ≤25 mm Hg (P=0.040; n=254, with missing values for 83 patients); central venous pressure/pulmonary capillary wedge pressure ratio >0.4 (P=0.022; n=176; with missing values for 161 patients); and mild, moderate, and severe right ventricular dysfunction (P=0.0004; n=260; with 77 patients missing values). An attempt was made to complete the multivariable analysis by forcing in these incomplete variables. The model ended up losing more than half the patients because the model requires complete data for all variables in the model, otherwise the entire patient is eliminated from the model. However, even with a less than ideal final n=113 patients, the risk factor of TR severity was still the strongest predictor (P<0.0001), whereas baseline pulmonary artery diastolic pressure ≤25 mm Hg was also a predictor (P=0.0076). Female sex was no longer a predictor in this limited model.
Discussion
In the ADVANCE BTT and CAP trials, TVP was the most common type of concurrent valve intervention performed with HVAD implantation. Consistent with findings from other studies, concurrent valve procedures did not affect overall mortality or length of intensive care unit or hospital stay. 14, [17] [18] [19] This study shows no increased mortality for HVAD alone versus HVAD plus AVP. In contrast to our findings, Pal et al 9 previously noted significantly increased mortality in a group of 12 patients undergoing AVP during implantation of an axial-flow cf-LVAD. A more recent study by John et al 8 also noted higher overall mortality in 281 patients who had concurrent valve procedures during implantation of the axial-flow cf-LVAD, principally driven by increased mortality in patients receiving concurrent AVP. 
S10 Circulation
September 9, 2014
However, our finding that the incidence of early RHF increased in patients undergoing concurrent valve procedures was consistent with John et al. 8 Our multivariable analysis found that baseline moderate/severe tricuspid insufficiency and sex were significant independent predictors of RHF, but that concurrent valve procedures during HVAD implantation were not, in themselves, predictive for development of RHF. Interestingly, Piacentino et al 13 have provided data that suggest that concurrent TVP actually reduces the risk of RHF relative to patients who have significant preimplant TR but undergo LVAD alone. We also found that baseline diastolic pulmonary artery pressure ≤25 mm Hg was a univariable predictor of RHF as was central venous pressure/pulmonary capillary wedge pressure ratio >0.4 and any reduction in RV function. These risk factors were identified in previous models of RHF. 20 Because decisions to treat valve pathology were made by individual surgeons according to clinical judgment, 71 patients were diagnosed with moderate to severe TR, as identified by preimplant echocardiography, but who were not treated with TVP. According to recent International Society for Heart and Lung Transplantation guidelines, these patients should have been considered for concurrent TVP. 7 Compared with the TVP group, this cohort experienced greater late RHF. Therefore, the present results support International Society for Heart and Lung Transplantation guidelines that for moderate or greater TR, the tricuspid valve should be repaired at the time of LVAD implantation. 7, 9, 11, 19 The results also support the studies by Piacentino et al, 10, 12, 13 which suggest that TVP may help to mitigate RHF for patients with moderate to severe preimplant TR relative to those who do not receive TVP.
Limitations
This study is a post hoc analysis of an existing data set, and therefore, the patient selection criteria and data collection methods were not specifically designed for this analysis. As a consequence, the diagnostic criteria used to guide clinical decisions regarding valve procedures were not prespecified and were instead left to individual surgeon discretion. Furthermore, the specific procedure types (repair versus replacement) were not recorded or tabulated or was there any assessment of the success rates for the different procedures. For example, it is unclear whether TVP resulted in elimination of significant TR for the majority of patients. Finally, demographic differences between groups and the small size of patient subsets may have confounded results.
Despite these limitations, this study suggests that the increased risk of RHF for patients undergoing heart valve procedures at the time of HVAD implant is likely related to the severity of tricuspid valve insufficiency, rather than the added valve procedure per se. Furthermore, the addition of TVP may lessen the risk of late RHF development. This study adds to a growing body of evidence suggesting that concurrent valve procedures can be performed safely at time of LVAD implantation without increased morbidity or mortality.
